Literature DB >> 11172340

Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture.

K Breitkopf1, B Lahme, C G Tag, A M Gressner.   

Abstract

Latent transforming growth factor beta binding protein (LTBP), a high-molecular-weight glycoprotein of the large latent TGF-beta complex is suggested to serve as an anchor for latent TGF-beta in the extracellular matrix and as a component of microfibrillar structures. Proteolytic cleavage of LTBP is supposed to be a prerequisite for the release and generation of bioactive (mature) TGF-beta. We investigated the expression of LTBP isoforms in normal and fibrotic rat liver and in cultured rat hepatic stellate cells (HSC) transdifferentiating to myofibroblasts (MFB). We further determined their interaction with the matrix and some of their basic functions. Immunostainings of normal and fibrotic livers demonstrate intense signals for LTBP-1 and -2, preferably in parenchymal, but also nonparenchymal, cells and in fibrotic extracellular matrix. However, in situ hybridization points to a restriction of transcripts to nonparenchymal cells from fibrotic livers, whereas hepatocytes were always devoid of LTBP transcripts. The findings were confirmed by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR), which showed isoform-specific increases of LTBP transcripts in cultured stellate cells transdifferentiating to MFB and by Northern blot analyses showing the absence of LTBP-1 mRNA in freshly isolated hepatocytes. Using a cell enzyme-linked immunosorbent assay (ELISA), a differential increase of partly deoxycholate (DOC)-resistant, matrix-bound LTBP-1 and -2 was measured in cultured stellate cells. Treatment with plasmin generated soluble LTBP-1 and bioactive TGF-beta, which was able to induce Smad7 expression in an autocrine fashion. Our data propose (transdifferentiating) stellate cells, respectively MFB, as the major source of LTBP in normal and fibrotic liver, which here probably fulfills structural and TGF-beta-regulating functions as suggested for nonhepatic tissues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172340     DOI: 10.1053/jhep.2001.21996

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

Review 1.  Immunomodulatory effects of transforming growth factor-β in the liver.

Authors:  Hans-Theo Schon; Ralf Weiskirchen
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

2.  Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells.

Authors:  K Breitkopf; I Sawitza; J H Westhoff; L Wickert; S Dooley; A M Gressner
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

3.  Quantitative analysis of transforming growth factor beta 1 mRNA in patients with alcoholic liver disease.

Authors:  Wei-Xing Chen; You-Ming Li; Chao-Hui Yu; Wei-Min Cai; Min Zheng; Feng Chen
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

4.  Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B.

Authors:  Ping Liu; Yi-Yang Hu; Cheng Liu; Da-Yuan Zhu; Hui-Ming Xue; Zhi-Qiang Xu; Lie-Ming Xu; Cheng-Hai Liu; Hong-Tu Gu; Zhi-Qing Zhang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

Review 5.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

6.  Emerging role of adipokine apelin in hepatic remodelling and initiation of carcinogensis in chronic hepatitis C patients.

Authors:  Rola M Farid; Riham M Abu-Zeid; Ahmed El-Tawil
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

7.  Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.

Authors:  Jordi Colmenero; Ramón Bataller; Pau Sancho-Bru; Marlene Domínguez; Montserrat Moreno; Xavier Forns; Miquel Bruguera; Vicente Arroyo; David A Brenner; Pere Ginès
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

8.  Effects of heparin on liver fibrosis in patients with chronic hepatitis B.

Authors:  Jun Shi; Jing-Hua Hao; Wan-Hua Ren; Ju-Ren Zhu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

9.  Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.

Authors:  Bin-Bin Zhang; Wei-Min Cai; Hong-Lei Weng; Zhong-Rong Hu; Jun Lu; Min Zheng; Rong-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

10.  Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children.

Authors:  Yasser E Nassef; Mones M Abu Shady; Essam M Galal; Manal A Hamed
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.